+ 0.70
+ 0.47%

Citi Downgrades Regeneron, Citing 'Underappreciated' Risk

December 1, 2017 9:57 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced Monday the failure and discontinuation of two trials for angiopoietin2. Between this and rising rivals, Regeneron bears are emerging.

The Rating

Citigroup analyst Robyn Karnauskas downgraded Regeneron from Buy to Neutral and lowered the price target from $480 to $380.

The Thesis

Citigroup considers the threat of Novartis AG (ADR) (NYSE:NVS)’s RTH258 to Eylea sales underappreciated, particularly amid the Ang2 failure.

“We find it hard to believe that in current day and age RTH258 would not have a price impact, at minimum,” Karnauskas said in a Friday note, projecting a 25-percent price impact and 10-percent share impact. (See Karnauskas' track record here.) 

With RTH258 in the picture, Citigroup forecasts Regeneron striking just $380 per share. Unrivaled, it could break $490, the analyst said. 

The competitive setback to Eylea could be partially offset by Dupi sales, which Karnauskas anticipates generating $1.03 billion in 2018 against consensus estimates of $924 million. Physician surveys indicate an impending increase in prescriptions for both adults and adolescents.

“Given the bullish Dupi survey and unchallenged Eylea for next two years, investors may not worry just yet,” Karnauskas said. “However, we see RTH258 threat as real and do not see transformative catalysts near term. We like REGN long term as this is the only large cap company with self-sustainable innovation.”

Price Action

At the time of publication, Regeneron was trading up slightly at $364.60.

Related Links:

Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings

Regeneron Surrenders Most Early Gains After Q3 Beat

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Related Articles

Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst.  read more

Why Regeneron's Growth Opportunity Is Unappreciated

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were advancing Monday following a sell-side upgrade and the news of President Donald Trump being administ read more

October FDA, CDC Meetings On Coronavirus Vaccines Set Stage For Emergency Use Authorization

Even as the world — and investors — await a coronavirus vaccine, the timeline has become increasingly hard to gauge given clinical setbacks and the risks inherent with fast development.  read more

Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs. read more